These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33150829)

  • 1. High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients.
    Schneider-Hohendorf T; Schulte-Mecklenbeck A; Ostkamp P; Janoschka C; Pawlitzki M; Luessi F; Zipp F; Meuth SG; Klotz L; Wiendl H; Gross CC; Schwab N
    Mult Scler; 2021 Sep; 27(10):1491-1496. PubMed ID: 33150829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy.
    Ngouth N; Monaco MC; Walker L; Corey S; Ikpeama I; Fahle G; Cortese I; Das S; Jacobson S
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
    Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V
    Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
    Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
    J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
    Jelcic I; Combaluzier B; Jelcic I; Faigle W; Senn L; Reinhart BJ; Ströh L; Nitsch RM; Stehle T; Sospedra M; Grimm J; Martin R
    Sci Transl Med; 2015 Sep; 7(306):306ra150. PubMed ID: 26400911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
    Skarlis C; Papadopoulos V; Raftopoulou S; Mavragani CP; Evangelopoulos ME
    J Neurol Sci; 2024 Jun; 461():123046. PubMed ID: 38761670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.
    Zingaropoli MA; Iannetta M; Pontecorvo S; Anzivino E; Prezioso C; Rodio DM; Morreale M; D'Abramo A; Oliva A; Lichtner M; Cortese A; Frontoni M; Pietropaolo V; Francia A; Mastroianni CM; Vullo V; Ciardi MR
    Biomed Res Int; 2018; 2018():5297980. PubMed ID: 29682547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
    Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
    Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum.
    Schweitzer F; Ladwig A; Opala S; Laurent S; Schroeter M; Goelz S; Fink GR; Wieland U; Silling S; Warnke C
    Mult Scler Relat Disord; 2024 Jul; 87():105664. PubMed ID: 38735204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
    Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
    Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O
    Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients.
    Agostini S; Mancuso R; Costa AS; Caputo D; Clerici M
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33809082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teriflunomide Inhibits JCPyV Infection and Spread in Glial Cells and Choroid Plexus Epithelial Cells.
    O'Hara BA; Gee GV; Haley SA; Morris-Love J; Nyblade C; Nieves C; Hanson BA; Dang X; Turner TJ; Chavin JM; Lublin A; Koralnik IJ; Atwood WJ
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.
    Diotti RA; Capra R; Moiola L; Caputo V; De Rossi N; Sangalli F; Martinelli V; Burioni R; Clementi M; Mancini N
    Viruses; 2016 May; 8(5):. PubMed ID: 27164128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
    Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
    Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML).
    Schneider R; Bellenberg B; Hoepner R; Kolb EM; Ellrichmann G; Haghikia A; Gold R; Lukas C
    PLoS One; 2017; 12(4):e0176415. PubMed ID: 28445498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
    Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study.
    Häusler D; Akgün K; Stork L; Lassmann H; Ziemssen T; Brück W; Metz I
    Brain Pathol; 2021 Nov; 31(6):e12969. PubMed ID: 33955606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.